Prasugrel 5mg

DRUG4 trials

Sponsors

Seoul National University Hospital, Attikon Hospital, Gyeongsang National University Hospital, Columbia University

Conditions

Acute Coronary SyndromeCoronary Artery DiseaseDiabetes MellitusMigraine DiseaseMyocardial InfarctionPatent Foramen OvaleRenal Disease

Phase 3

Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy

Not yet recruitingNCT07629635

Columbia UniversityMigraine Disease, Patent Foramen Ovale

Start: 2026-09-01End: 2028-03-01Target: 32Updated: 2026-06-05

Phase 4

Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)

CompletedNCT02193971

Seoul National University HospitalAcute Coronary Syndrome

Start: 2014-07-01End: 2024-01-01Updated: 2026-04-27

Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction

CompletedNCT03387826

Attikon HospitalCoronary Artery Disease, Diabetes Mellitus, Myocardial Infarction +1

Start: 2018-01-11End: 2019-01-31Updated: 2019-03-05

Prasugrel 5 mg vs. Ticagrelor 60 mg in CHIP (E5TION)

Gyeongsang National University HospitalCoronary Artery Disease

Start: 2020-01-15End: 2022-06-15Target: 492Updated: 2021-02-02

Related Papers

Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial

European Heart Journal - Cardiovascular Pharmacotherapy2023-01-285 citations

Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome

JAMA Cardiology2022-03-0921 citations

Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome

Circulation2020-11-1854 citations

Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial.

2020-08-31140 citations

Harmonizing Optimal Strategy for Treatment of coronary artery diseases – comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial

Trials2015-09-1514 citations